Companies /Healthcare

Staar Surgical Company

NASDAQ: STAA Medical Instruments & Supplies
$26.01
▼ $0.38 (−1.44%) today
Markets closed · 5:09pm ET

STAA at a Glance

Valuation
Market cap
$1.3B
P/E ratio
2,639.0
Profitability
Revenue (TTM)
$328.3M
Profit margin
0.2%
EPS (TTM)
$0.01
Price
52-week range
$16 – $36
Street target
$28.56

Headquartered in Lake Forest, CA Fiscal year ends December NASDAQ: STAA staar.com

About STAAR Surgical

STAAR Surgical Company designs, develops, manufactures and markets implantable phakic intraocular lenses (IOLs) for vision correction. The lenses reduce or eliminate the need for glasses or contact lenses. Its core product is the EVO family of Implantable Collamer Lenses (EVO ICL), made from the company's proprietary biocompatible Collamer material. The lenses correct vision without removing corneal tissue or the eye's natural crystalline lens, through a quick, minimally invasive and reversible procedure.

STAAR has focused solely on ophthalmic surgery since 1982. It has distributed more than 4 million ICLs in over 85 countries.

The business depends heavily on Asia Pacific, especially China, its largest market, where it sells through independent distributors. The China mix is shifting toward the premium EVO+ and toric lenses. Japan, South Korea, the United States and EMEA (including Spain, Germany and the UK) are other important markets.

The company runs manufacturing in Monrovia, California and Nidau, Switzerland. All China-bound lenses are now made in Switzerland to reduce tariff exposure.

STAAR is investing in next-generation presbyopia technologies, with first-in-human trials expected soon. It is also pursuing label expansions, including raising U.S. eligibility to age 60 and lowering the Brazil prescription minimum to −0.5 diopters. It positions EVO ICL as driving a market shift from laser-based to lens-based refractive surgery.

The company has no debt. Its proposed merger with Alcon was terminated in January 2026. Updated

Latest Activity

STAASTAAR Surgical
Q3 2026
EPS
$0.11
est $0.17-34.8%
Revenue
$83M
est $79M+5.9%

Gross margin collapsed to 70.9% on ERP-related production costs, freight and China tariffs, which is why revenue topped estimates while earnings missed expectations. Management says the margin squeeze starts easing in Q4, and all China-bound lens production has moved to Switzerland to sidestep tariffs.

Quarterly EPS — reported vs estimate

STAA Coverage

Frequently Asked Questions

What does STAAR Surgical do?

STAAR Surgical Company designs, develops, manufactures and markets implantable phakic intraocular lenses (IOLs) for vision correction. The lenses reduce or eliminate the need for glasses or contact lenses.

What is the STAA stock price target?

The Wall Street consensus 12-month price target for STAA is $28.56.